Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prothrombin complex concentrate (human) is a human plasma-derived biologic product containing vitamin K-dependent coagulation factors — primarily Factor II (prothrombin), Factor IX, and Factor X, and potentially Factor VII. Developed by Hebei Da'an Pharmaceutical Co., Ltd., it is used to treat hemophilia B (Factor IX deficiency) by replacing the deficient factors and restoring the coagulation cascade. The drug is a 3- or 4-factor prothrombin complex concentrate (PCC) administered by intravenous injection. It is currently being evaluated in a Phase 3, single-arm, open-label clinical trial in China (CTR20180124) to assess its efficacy and safety in treating hemophilia B using an objective performance criterion (target value method).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on prothrombin complex concentrate (human) (Hebei Da'an Pharmaceutical).